Compare Stocks

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase 1/2a trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.

Huttig Building Products, Inc., together with its subsidiaries, distributes millwork, building materials, and wood products for new residential construction, in-home improvement, remodeling, and repair works in the United States. The company offers various millwork products, including exterior and interior doors, pre-hung and factory finished door units, windows, patio doors, mouldings, frames, stair parts, and columns under the Therma-Tru, Masonite, Woodgrain, HB&G, Simpson Door, Final Frame, BrasPine, Arauco, Windsor Windows, and Rogue Valley Door brands. It also provides general building products, such as fasteners and connectors, roofing, siding, insulation, flashing, housewrap, decking, railings, and other miscellaneous building products under the Huttig-Grip, Louisiana-Pacific, Simpson Strong-Tie, TimberTech, AZEK, RDI, GAF Roofing, Maibec, Knauf, GCP Technologies, Fiberon, Alpha Protech, MFM, Lomanco, and Fortifiber brands. In addition, the company offers wood products comprising engineered wood products used in floor systems, wood panels, and lumber; and value-added services, such as floor system take-offs, cut-to-length packages and just-in-time, and cross-dock delivery under the Louisiana-Pacific and Rosboro brands. It markets and sells its products through a network of 25 wholesale distribution centers serving approximately 41 states to building materials dealers, national buying groups, home centers, and industrial users comprising makers of manufactured homes. Huttig Building Products, Inc. was founded in 1865 and is headquartered in St. Louis, Missouri.

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; and peptide production for subsequent antibody discovery campaign. In addition, it provides B cell select platform which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and select the desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection. The company also offers phage display, a custom immune libraries from multiple species; and CAR development, an adaptable antibody which allows the inclusion of functional data early in the screening funnel. Further, it provides silico developability, a profiling toolset for antibody lead candidates; and vitro analytical tools for the study of various critical quality attributes. Additionally, the company offers LucinaTech, an antibody humanization to identify essential framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; and antibody chimerization for cloning and production of variable antibody domain. It also provides Eurofins preclinical services; hybrid service model, a service model designed to reduce time and risk with custom technologies and applications; and breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts. The company was incorporated in 1983 and is headquartered in Victoria, Canada.

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young, healthy adult donors. It is conducting Phase 1, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is headquartered in Miami, Florida.

Veresen Inc is a Canada-based energy infrastructure company that owns and operates energy infrastructure assets across North America. The Company is engaged in three principal businesses: a pipeline transportation business consists of interests in the Alliance Pipeline, the Ruby Pipeline and the Alberta Ethane Gathering System (AEGS); a midstream business, which includes a partnership interest in Veresen Midstream Limited Partnership, which owns assets in western Canada, and an ownership interest in Aux Sable, which owns a natural gas liquids (NGL) extraction facility near Chicago, and other natural gas and NGL processing energy infrastructure, and a power business consists of a portfolio of assets in Canada. The Company's segments include Pipelines, Midstream, Power and Corporate. Alliance Pipeline owns and manages an integrated, high-pressure natural gas and NGL pipeline. Ruby Pipeline is a natural gas transmission system. AEGS is an integrated pipeline system.